Skip to main content

Table 3 Clinical measures

From: Sleep architecture and cognitive changes in olanzapine-treated patients with depression: A double blind randomized placebo controlled trial

 Clinical measures

Placebo

Olanzapine

Baseline

Day 2-4

Day 28-31

Baseline

Day 2-4

Day 28-31

ANOVA

Mean ± SD

Mean ± SD

MADRS total

26 ± 6.3

26 ± 7.1

24 ± 3.2

25 ± 5.8

23 ± 6.2

19 ± 11

p = .175

HDRS total

21 ± 5.5

19 ± 5.9

18 ± 7.4

22 ± 5.0

18 ± 6.4

15 ± 8.4

p = .123

HARS total

16 ± 2.9

13 ± 4.7

13 ± 5.3

17 ± 5.8

15 ± 7.4

13 ± 6.7

p = .420

YMRS total

3.9 ± 3.4

3.7 ± 2.5

4.7 ± 4.2

3.7 ± 3.1

2.9 ± 3.0

3.5 ± 2.3

p = .223

PSQI total

13 ± 3.0

14 ± 3.6

12 ± 5.2

12 ± 3.5

11 ± 4.2

9.9 ± 4.7

p = .699

VAS total

31 ± 15

32 ± 19

43 ± 27

37 ± 27

45 ± 28

59 ± 30

p = .415

ESS total

7.4 ± 6.2

5.4 ± 4.2

5.8 ± 5.9

8.4 ± 5.2

8.5 ± 5.6

7.3 ± 5.2

p = .666

  1. The mean ± standard deviation (SD) of selected clinical measures for both olanzapine and placebo treated group. MADRS = Montgomery Asberg Depression Rating Scale, HDRS = Hamilton Depression Rating Scale, HARS = Hamilton Anxiety Rating Scale, YMRS = Young Mania Rating Scale, VAS = Visual Analogue Scale for sleep quality, PSQI = Pittsburg Sleep Quality Index, ESS = Epworth Sleepiness Scale. P value reported for the interaction (time by treatment) of a two-way repeated measures ANOVA.
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us